TScan Starts Pivotal TSC-101 Trial
TScan Therapeutics dosed the first patient in ALLOHA-2, its pivotal Phase 3 trial of TSC-101 after allogeneic hematopoietic cell transplantation for AML or MDS. The milestone moves a donor-derived, HA-2-directed TCR-T strategy into registrational…
